Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy
NCT04745728Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in idiopathic membranous nephropathy (IMN), sponsored by Peking Union Medical College Hospital. Started Apr 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT04745728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745728.